

LncRNA HLA Complex Group II Knockdown Alleviates Cisplatin Resistance in Gastric Cancer by Targeting the miR-144-3p/UBE2D1 Axis [Retraction]

Li Y, Wang L, Xu X, Sun H, Wu L. *Cancer Manag Res.* 2021;13:7543–7557.

We, the Editors and Publisher of *Cancer Management and Research*, have retracted the following article.

Since publication, concerns have been raised about the integrity of the data in the article. This includes the duplication of images for Figure 7. Specifically,

- The image for Figure 7, MKN45/DDP, sh-HCG11+miR-144-3p inhibitor has overlap with the image for Figure 7, MKN45/DDP, sh-HCG11+pcDNA-UBE2D1.

When approached for an explanation, the authors did not respond to our queries, nor did they provide original data for their study. As verifying the validity of the published work is core to the integrity of the scholarly record, we are therefore retracting the article and the authors were notified of this.

We have been informed in our decision-making by our editorial policies and COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

Publish your work in this journal

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/cancer-management-and-research-journal>

<https://doi.org/10.2147/CMAR.S438016>

